share_log

Recursion Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144

SEC announcement ·  Jun 26 04:26
Summary by Futu AI
Recursion Pharmaceuticals, Inc. Director Blake Borgeson is set to sell 11,447 Class A shares of the company on 06/25/2024, as per the latest filing. The shares, valued at approximately $108,805.92, were originally acquired as founders shares on 09/01/2016 as part of compensation from the issuer. This planned sale follows a series of transactions over the past three months, where a total of 77,289 shares were sold for gross proceeds of $684,271.04. The notice of the upcoming sale was filed on the same date as the planned sale, with the instruction for this transaction given on 08/18/2023.
Recursion Pharmaceuticals, Inc. Director Blake Borgeson is set to sell 11,447 Class A shares of the company on 06/25/2024, as per the latest filing. The shares, valued at approximately $108,805.92, were originally acquired as founders shares on 09/01/2016 as part of compensation from the issuer. This planned sale follows a series of transactions over the past three months, where a total of 77,289 shares were sold for gross proceeds of $684,271.04. The notice of the upcoming sale was filed on the same date as the planned sale, with the instruction for this transaction given on 08/18/2023.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.